274 related articles for article (PubMed ID: 16223957)
1. The novel imidazopyridine 2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase.
Strub A; Ulrich WR; Hesslinger C; Eltze M; Fuchss T; Strassner J; Strand S; Lehner MD; Boer R
Mol Pharmacol; 2006 Jan; 69(1):328-37. PubMed ID: 16223957
[TBL] [Abstract][Full Text] [Related]
2. BYK191023 (2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3h-imidazo[4,5-b]pyridine) is an NADPH- and time-dependent irreversible inhibitor of inducible nitric-oxide synthase.
Tiso M; Strub A; Hesslinger C; Kenney CT; Boer R; Stuehr DJ
Mol Pharmacol; 2008 Apr; 73(4):1244-53. PubMed ID: 18178668
[TBL] [Abstract][Full Text] [Related]
3. In vivo characterization of the novel imidazopyridine BYK191023 [2-[2-(4-methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine], a potent and highly selective inhibitor of inducible nitric-oxide synthase.
Lehner MD; Marx D; Boer R; Strub A; Hesslinger C; Eltze M; Ulrich WR; Schwoebel F; Schermuly RT; Barsig J
J Pharmacol Exp Ther; 2006 Apr; 317(1):181-7. PubMed ID: 16368897
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of nitric oxide synthase by 1-(2-trifluoromethylphenyl) imidazole (TRIM) in vitro: antinociceptive and cardiovascular effects.
Handy RL; Harb HL; Wallace P; Gaffen Z; Whitehead KJ; Moore PK
Br J Pharmacol; 1996 Sep; 119(2):423-31. PubMed ID: 8886430
[TBL] [Abstract][Full Text] [Related]
5. N-Phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: structure-activity studies and demonstration of in vivo activity.
Collins JL; Shearer BG; Oplinger JA; Lee S; Garvey EP; Salter M; Duffy C; Burnette TC; Furfine ES
J Med Chem; 1998 Jul; 41(15):2858-71. PubMed ID: 9667974
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes.
Boer R; Ulrich WR; Klein T; Mirau B; Haas S; Baur I
Mol Pharmacol; 2000 Nov; 58(5):1026-34. PubMed ID: 11040050
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of new sulfur-containing L-arginine-derived inhibitors of nitric oxide synthase.
Ichimori K; Stuehr DJ; Atkinson RN; King SB
J Med Chem; 1999 May; 42(10):1842-8. PubMed ID: 10346937
[TBL] [Abstract][Full Text] [Related]
8. Aromatic reduced amide bond peptidomimetics as selective inhibitors of neuronal nitric oxide synthase.
Hah JM; Martásek P; Roman LJ; Silverman RB
J Med Chem; 2003 Apr; 46(9):1661-9. PubMed ID: 12699384
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide synthase isoform inhibition before whole body ischemia reperfusion in pigs: vital or protective?
Adams JA; Wu D; Bassuk J; Arias J; Lozano H; Kurlansky P; Lamas GA
Resuscitation; 2007 Sep; 74(3):516-25. PubMed ID: 17466432
[TBL] [Abstract][Full Text] [Related]
10. 1-(1,3-Benzodioxol-5-ylmethyl)-3-[4-(1H-imidazol-1-yl)phenoxy]-piperidine analogs as potent and selective inhibitors of nitric oxide formation.
Wei RG; Adler M; Davey D; Ho E; Mohan R; Polokoff M; Tseng JL; Whitlow M; Xu W; Yuan S; Phillips G
Bioorg Med Chem Lett; 2007 May; 17(9):2499-504. PubMed ID: 17368901
[TBL] [Abstract][Full Text] [Related]
11. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
[TBL] [Abstract][Full Text] [Related]
12. Involvement of endogenous nitric oxide in the regulation of K+ channel activity in cultured human proximal tubule cells.
Nakamura K; Habano W; Kojo T; Komagiri Y; Kubota T; Kubokawa M
J Physiol Sci; 2006 Dec; 56(6):407-13. PubMed ID: 17062169
[TBL] [Abstract][Full Text] [Related]
13. Pyrazoles and pyrazolines as neural and inducible nitric oxide synthase (nNOS and iNOS) potential inhibitors (III).
Carrión MD; López Cara LC; Camacho ME; Tapias V; Escames G; Acuña-Castroviejo D; Espinosa A; Gallo MA; Entrena A
Eur J Med Chem; 2008 Nov; 43(11):2579-91. PubMed ID: 18325637
[TBL] [Abstract][Full Text] [Related]
14. The effect of nitric oxide inhibition and temporal expression patterns of the mRNA and protein products of nitric oxide synthase genes during in vitro development of bovine pre-implantation embryos.
Tesfaye D; Kadanga A; Rings F; Bauch K; Jennen D; Nganvongpanit K; Hölker M; Tholen E; Ponsuksili S; Wimmers K; Montag M; Gilles M; Kirfel G; Herzog V; Schellander K
Reprod Domest Anim; 2006 Dec; 41(6):501-9. PubMed ID: 17107508
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a series of aminopiperidines as novel iNOS inhibitors.
Le Bourdonnec B; Leister LK; Ajello CA; Cassel JA; Seida PR; O'Hare H; Gu M; Chu GH; Tuthill PA; DeHaven RN; Dolle RE
Bioorg Med Chem Lett; 2008 Jan; 18(1):336-43. PubMed ID: 18024030
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of nitric oxide synthase isoforms by porphyrins.
Wolff DJ; Naddelman RA; Lubeskie A; Saks DA
Arch Biochem Biophys; 1996 Sep; 333(1):27-34. PubMed ID: 8806750
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of selective and non-selective inhibition of nitric oxide synthase on the expression and activity of cyclooxygenase-2 during gastric ulcer healing.
Guo JS; Cho CH; Wang JY; Koo MW
Eur J Pharmacol; 2006 May; 536(3):301-8. PubMed ID: 16600210
[TBL] [Abstract][Full Text] [Related]
18. N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase.
Huang H; Martasek P; Roman LJ; Masters BS; Silverman RB
J Med Chem; 1999 Aug; 42(16):3147-53. PubMed ID: 10447959
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters.
Silverman RB; Huang H; Marletta MA; Martasek P
J Med Chem; 1997 Aug; 40(18):2813-7. PubMed ID: 9288162
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases.
Symons KT; Nguyen PM; Massari ME; Anzola JV; Staszewski LM; Wang L; Yazdani N; Dorow S; Muhammad J; Sablad M; Rozenkrants N; Bonefous C; Payne JE; Rix PJ; Shiau AK; Noble SA; Smith ND; Hassig CA; Zhang Y; Rao TS
J Pharmacol Exp Ther; 2011 Feb; 336(2):468-78. PubMed ID: 21036913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
